High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and efficacy of high dose inorganic selenium in
preventing and relieving chemotherapy-induced peripheral neuropathy (CIPN) in
platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer patients. This
study will be conducted as a phase III randomized controlled trial in platinum-sensitive
recurrent ovarian, fallopian, or primary peritoneal cancer patients who are expected to
undergo paclitaxel-carboplatin chemotherapy. A total of 68 patients need to be enrolled in
this study. The primary objective of this study is to evaluate the frequency of
chemotherapy-induced peripheral neuropathy. The secondary objectives are the evaluation of
the severity of peripheral neuropathy and the quality of life to show that selenium is
effective in preventing and relieving peripheral neuropathy induced by paclitaxel. Positive
results in this study will lead to further studies investigating the effect of selenium on
other chemotherapies that can induce peripheral neuropathy.